| abstract |
The invention relates to a novel peptide, polypeptide or monoclonal antibody for use in the treatment of conditions characterised by elevated levels of β-amyloid (Aβ 39-43 amino acid peptide) in a subject, especially Alzheimer's Disease. The invention particularly relates to an amyloid precursor protein (APP) -binding polypeptide which, when administered outside an APP-expressing cell, reduces the release of Aβ 39-43 by the cell. |